National Capital Clinical Research Consortium

Bethesda, Maryland 20817

0 studies enrolling now · 16 studies all time

What they study most

Breast Cancer, Chronic Lymphocytic Leukemia, Extensive-Stage Small Cell Lung Cancer, Lymphoma, Lymphoma, Follicular, Metastatic Breast Cancer, Multiple Myeloma, Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer

Studies at this site

• Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer — Completed
• Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer — Completed
• Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy — Completed
• Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy — Completed
• Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer — Completed
• Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) — Completed
• Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer — Completed
• Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma — Completed
• Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC — Completed
• A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer — Completed
• Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib — Completed
• Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer — Completed
• A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma — Completed
• Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer — Completed
• Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer — Completed
• Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer — Completed